Disease · MONDO_0006519
rectal cancer
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. rectal cancer. Diseases, record MONDO_0006519. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006519
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
cancer of rectum, carcinoma of rectum, carcinoma of the rectum, malignant neoplasm of rectum, malignant neoplasm of the rectum, malignant rectal neoplasm, malignant rectal tumor, malignant rectal tumour, malignant rectum neoplasm, malignant rectum tumor, malignant rectum tumour, malignant tumor of rectum, malignant tumor of the rectum, malignant tumour of rectum, malignant tumour of the rectum, rectum cancer
- Open Targets
Drugs140
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CAPECITABINE | CHEMBL1773 | Small molecule | Phase 3 | ClinicalTrials.gov | 264 | 264 | 260 | Drugs and targets |
| OXALIPLATIN | CHEMBL414804 | Small molecule | Phase 3 | ClinicalTrials.gov | 244 | 244 | 221 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 3 | ClinicalTrials.gov | 162 | 162 | 139 | Drugs and targets |
| IRINOTECAN | CHEMBL481 | Small molecule | Phase 3 | ClinicalTrials.gov | 68 | 68 | 57 | Drugs and targets |
| LEUCOVORIN | CHEMBL1679 | Small molecule | Phase 3 | ClinicalTrials.gov | 51 | 51 | 37 | Drugs and targets |
| LEUCOVORIN CALCIUM | CHEMBL1201138 | Small molecule | Phase 3 | ClinicalTrials.gov | 40 | 40 | 31 | Drugs and targets |
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Phase 3 | ClinicalTrials.gov | 39 | 39 | 39 | Drugs and targets |
| TISLELIZUMAB | CHEMBL4297840 | Antibody | Phase 3 | ClinicalTrials.gov | 28 | 28 | 28 | Drugs and targets |
| FOLINIC ACID | CHEMBL1232801 | Small molecule | Phase 3 | ClinicalTrials.gov | 24 | 24 | 14 | Drugs and targets |
| SERPLULIMAB | CHEMBL4594550 | Antibody | Phase 3 | ClinicalTrials.gov | 13 | 13 | 13 | Drugs and targets |
1 to 10 of 140
See all 140 drugsTargets205
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PDCD1 | Programmed cell death protein 1 | 15 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 3 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 10 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2/3 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 9 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2/3 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 8 | Vascular endothelial growth factor receptor inhibitor | Phase 2/3 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 7 | Stem cell growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 7 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| CD274 | Programmed cell death 1 ligand 1 | 5 | Programmed cell death 1 ligand 1 binding agent; Programmed cell death 1 ligand 1 inhibitor; Programmed cell death 1 ligand 1 other | Phase 2/3 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| TYMS | Thymidylate synthase | 5 | Thymidylate synthase inhibitor | Phase 3 | https://conductscience.org/library/genes/7298 | Drugs and targets |
| EGFR | Epidermal growth factor receptor | 4 | Epidermal growth factor receptor erbB1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| ERBB2 | Receptor tyrosine-protein kinase erbB-2 | 4 | Receptor protein-tyrosine kinase erbB-2 cross-linking agent; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor tyrosine-protein kinase erbB-2 binding agent | Phase 2 | https://conductscience.org/library/genes/2064 | Drugs and targets |
1 to 10 of 205
See all 205 targetsTrials472
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 12 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01515787 | PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery | Phase 2/3 | 1,194 | 2024-02-02 | Colorectal Cancer | CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT02921256 | Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer | Phase 2 | 363 | 2023-06-09 | Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v7, Stage III Rectal Cancer AJCC v7 | CAPECITABINE, FLUOROURACIL, LEUCOVORIN CALCIUM, OXALIPLATIN, PEMBROLIZUMAB, VELIPARIB | Its record names the disease | ClinicalTrials.gov |
| NCT00303628 | Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer | Phase 3 | 355 | 2016-02-26 | Adenocarcinoma of the Rectum, Stage II Rectal Cancer, Stage III Rectal Cancer | BEVACIZUMAB, FLUOROURACIL, LEUCOVORIN CALCIUM, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT00807911 | Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer | Phase 2 | 322 | 2024-10-23 | Rectal Cancer | FLUOROURACIL, LEUCOVORIN, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT01830621 | BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma | Phase 3 | 282 | 2019-03-11 | Colorectal Carcinoma | NAPABUCASIN | Its record names the disease | ClinicalTrials.gov |
| NCT00068692 | Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer | Phase 3 | 225 | 2018-12-04 | Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma, Recurrent Rectal Carcinoma, Stage IIA Rectal Cancer AJCC v7, Stage IIB Rectal Cancer AJCC v7, Stage IIC Rectal Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Rectal Cancer AJCC v7 | FLUOROURACIL, IRINOTECAN, LEUCOVORIN CALCIUM, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT00081289 | Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer | Phase 2 | 146 | 2013-11-25 | Colorectal Cancer | CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT01507103 | Tecemotide (L-BLP25) in Rectal Cancer | Phase 2 | 124 | 2016-06-02 | Rectal Cancer | TECEMOTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00865189 | A Study of Bevacizumab (Avastin) in Participants With Newly Diagnosed Locally Advanced Rectal Cancer | Phase 2 | 91 | 2017-08-04 | Rectal Cancer | BEVACIZUMAB, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT00114231 | Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer | Phase 2 | 90 | 2018-03-29 | Colorectal Cancer | CAPECITABINE, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 472
See all 472 trialsComparisons in its trials43
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Group 1 vs Group 2: Overall Survival | 74 of 585 | 67 of 543 | 1,128 | NCT01515787 | Trial comparisons |
| Group 1 vs Group 2: DFS | 114 of 585 | 113 of 543 | 1,128 | NCT01515787 | Trial comparisons |
| Group 1 vs Group 2: Local Recurrence (TLR): | 9 of 585 | 7 of 543 | 1,128 | NCT01515787 | Trial comparisons |
| Group 1 vs Group 2: Rates of Receiving Pre- or Post-operative 5FUCMT | 61 of 585 | 543 of 543 | 1,128 | NCT01515787 | Trial comparisons |
| Group 1 vs Group 2: deaths from any cause | 74 of 585 | 67 of 543 | 1,128 | NCT01515787 | Trial comparisons |
| Group 1 vs Group 2: serious adverse events | 10 of 585 | 7 of 543 | 1,128 | NCT01515787 | Trial comparisons |
| Group 1 vs Group 2: Pelvic R0 Resection Rate | 529 of 535 | 495 of 510 | 1,045 | NCT01515787 | Trial comparisons |
| Group 1 vs Group 2: Pathologic Complete Response | 117 of 535 | 124 of 510 | 1,045 | NCT01515787 | Trial comparisons |
| Arm I (Oxaliplatin, Fluorouracil, Leucovorin) vs Arm II (Oxaliplatin, Fluorouracil, Leucovorin, Bevacizumab): serious adverse events | 119 of 173 | 123 of 174 | 347 | NCT00303628 | Trial comparisons |
| Adjuvant Fluorouracil +Leucovorin vs Adjuvant FOLFOX: Death Rate | 21 of 161 | 10 of 160 | 321 | NCT00807911 | Trial comparisons |
1 to 10 of 43
See all 43 comparisons in its trialsPapers from its trials264
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006519
GET https://conductscience.org/api/diseases/v1/MONDO_0006519/drugs?page=2